We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Show more
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 PR Newswire VICTORIA, BC, July 3...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024 VICTORIA, BC, June 6, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 PR Newswire VICTORIA, BC, June 5, 2024...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, May 23, 2024 Eight of nine patients...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.113 | 4.70441298918 | 2.402 | 2.7 | 2.402 | 2873 | 2.50755684 | CS |
4 | -0.245 | -8.8768115942 | 2.76 | 3 | 2.402 | 11588 | 2.63294556 | CS |
12 | -0.365 | -12.6736111111 | 2.88 | 3.19 | 2.402 | 21063 | 2.83111365 | CS |
26 | -1.035 | -29.1549295775 | 3.55 | 3.55 | 2.402 | 24236 | 2.84520451 | CS |
52 | -1.035 | -29.1549295775 | 3.55 | 3.55 | 2.402 | 24236 | 2.84520451 | CS |
156 | -1.035 | -29.1549295775 | 3.55 | 3.55 | 2.402 | 24236 | 2.84520451 | CS |
260 | -1.035 | -29.1549295775 | 3.55 | 3.55 | 2.402 | 24236 | 2.84520451 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions